SuperworthAgenus EV/EBIT AGEN
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2021.
- Today, Oct 23, 2026
- 7.9×
- 5-year median
- 10.7×
- Against its 5-year history
- 17th
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 5.8× to 35.7×
- Peer median
- 9.2×
Agenus' EV/EBIT is 7.9× as of Oct 23, 2026.
That is below its 5-year median of 10.7×, lower than on 83% of days in the last 5 years.
Over that time it ranged from 5.8× in May 2022 to 35.7× in Jul 2026.
The median for 4 biotech stocks of a similar size is 9.2×.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 7.9× | 7.6× | 35.7× |
| 2025 | n/m a value too high to mean anything | ||
| 2024 | n/m a value too high to mean anything | ||
| 2023 | n/m a value too high to mean anything | ||
| 2022 | 10.2× | 5.8× | 18.8× |
| 2021 | 9.9× | 8.5× | 12.8× |
Against its peers
Companies in Biotechnology nearest Agenus' size, closest first, today.
| Company | EV/EBIT |
|---|---|
| AGENAgenus | 7.9× |
| PLXProtalix BioTherapeutics | 7.5× |
| MGTXMeiraGTx | 4.6× |
| VCELVericel | 116× |
| ADMAAdma Biologics | 10.9× |
| Peer median | 9.2× |
Where Agenus ranks
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on Agenus
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.